Dyspepsia Clinical Trial
Official title:
[13C]-Spirulina Platensis GEBT - Dual-Label Validation Study
Verified date | February 2013 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to compare stomach emptying using 13C-Spirulina platensis
breath test and scintigraphy in healthy subjects and subjects with dyspepsia.
Subjects will eat a standard meal of 2 scrambled eggs, a slice of wheat toast and 8 ounces
of skim milk. The eggs will be double labeled with Technetium-99m (99mTc) sulfur colloid and
13C-Spirulina platensis.
Scintigraphy is a diagnostic technique in which a two-dimensional picture of internal body
tissue is produced through the detection of radiation emitted by a radioactive substance
administered into the body. The location of a standard meal in the digestive system will be
measured by images of the 99mTc sulfur colloid taken at periodic intervals before and after
the standard meal. The 99mTc Sulfur Colloid is approved by the FDA for use in medical
diagnostic procedures.
Spirulina platensis is blue - green algae, which is very similar to the naturally occurring
spirulina sold in health food stores as a dietary supplement. The spirulina platensis has
been labeled with the 13C stable isotope. 13C stable isotope labeling is inherently safe as
1.1% of all carbon in our bodies and in the food we eat is 13C. The presence of the 13C will
be measured by breath samples at periodic intervals before and after a standard meal. The
FDA considers 13C-Spirulina platensis to be investigational for the purposes of this study.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Healthy male or non-pregnant, non-breastfeeding female volunteers - 18-70 years of age - Able to provide written informed consent before participating in the study - Able to communicate adequately with the Investigator and to comply with the requirements of for the entire study, i.e., able to eat test meal and provide breath samples. Additional inclusion criteria for dyspepsia patients: - One or more of eight postprandial dyspeptic symptoms i.e., fullness, bloating, epigastric discomfort, early satiety, nausea, vomiting, belching, pain for a minimum of 3 months, OR - Patients fulfilling the ROME-III criteria for functional dyspepsia, - AND no symptom improvement under a standard dose proton-pump inhibitor (PPI) treatment, - AND an upper gastrointestinal endoscopy negative for significant pathology that would explain symptoms done within the last 5 years prior to the study. Exclusion Criteria: - Severe nausea or vomiting precluding study assessments - Use of medications that alter GI motility e.g., narcotics or medications with significant anticholinergic effects within two days of the study - History of malabsorption due to mucosal disease, pancreatic disease, liver dysfunction, or other causes - Abdominal surgery other than appendectomy, cholecystectomy, tubal ligation or hysterectomy - Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that may interfere with the objectives of the study - Patients who are allergic to eggs, wheat, or milk, or unwilling to consume these products - Patients who have taken any investigational medications within the past 30 days. |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | Advanced Breath Diagnostics, LLC, National Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gastric Emptying Half Time Measured by Scintigraphy | Gastric emptying half time is the time for half of the ingested solids to leave the stomach. This value was measured by standard 99m Tc scintigraphy. | 4 hours after ingestion of standard meal | No |
Primary | Gastric Emptying Half Time Measured by 13C Spirulina Gastric Emptying Breath Test (GEBT) | Gastric emptying half time is the time for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT. | 4 hours after ingestion of standard meal | No |
Secondary | Gastric Emptying at 60, 120, and 240 Minutes Measured by Scintigraphy | The scintigraphic gastric emptying (GE) metric is the proportion of tracer emptied from the stomach at time, t. | 60, 120, and 240 minutes after ingestion of standard meal | No |
Secondary | Gastric Emptying at 60, 120, and 240 Minutes Measured by 13C Spirulina Gastric Emptying Breath Test (GEBT) | A multiple linear regression model approach was used to estimate gastric emptying based on the breath test samples at each time point. Gastric emptying (GE) metric is the proportion of tracer emptied from the stomach at time, t. | 60, 120, and 240 minutes after ingestion of standard meal | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Withdrawn |
NCT02863822 -
Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.
|
N/A | |
Recruiting |
NCT00978159 -
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
|
Phase 4 | |
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00148603 -
Montelukast in the Treatment of Duodenal Eosinophilia
|
N/A | |
Terminated |
NCT00220844 -
Tricyclic Antidepressants (TCAs) on Gastric Emptying
|
N/A | |
Completed |
NCT00110968 -
Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia
|
Phase 3 | |
Completed |
NCT00164996 -
Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia
|
Phase 3 | |
Completed |
NCT00232102 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00232037 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05718960 -
Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
|
N/A | |
Completed |
NCT05750641 -
The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
|
||
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Completed |
NCT03252743 -
ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.
|
N/A | |
Completed |
NCT04697641 -
Helicobacter Pylori Eradication in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|